13122-66-2

Basic information

• Product Name: (2R*,3S*)-2,3-dimethyl-4-oxo-4-phenylbutanoic acid
• Synonyms: (2R*,3S*)-2,3-dimethyl-4-oxo-4-phenylbutanoic acid
• CAS NO: 13122-66-2
• Molecular Weight: 206.241
• Mol File: 13122-66-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (2R*,3S*)-2,3-dimethyl-4-oxo-4-phenylbutanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2R*,3S*)-2,3-dimethyl-4-oxo-4-phenylbutanoic acid(13122-66-2)
• EPA Substance Registry System: (2R*,3S*)-2,3-dimethyl-4-oxo-4-phenylbutanoic acid(13122-66-2)

Safety Data

• Hazardous Substances Data: 13122-66-2(Hazardous Substances Data)

Upstream product

• 16844-07-8 meso-2,3-dimethylsuccinic anhydride 
• 71-43-2 benzene 
• 608-40-2 meso 2,3-dimethylsuccinic acid 
• 608-40-2 rac-2,3-dimethylsuccinic acid 
• 5866-20-6 trans-2,3-dimethylsuccinic anhydride 
• 7475-92-5 2,3-dimethylsuccinic anhydride 
• 86044-18-0 2,3-Dimethyl-4-oxo-4-phenylbutansaeure-methylester 
• 77-92-9 citric acid 

Downstream Products

• 86044-18-0 (+/-)-erythro-4-oxo-2.3-dimethyl-4-phenyl-butyric acid methyl ester 
• 34599-63-8 2,3-dimethyl-4-phenylbutanoic acid 
• 21564-92-1 2,3-dimethyl-1,2,3,4-tetrahydro-1-naphthol 
• 859196-82-0 2,3-dimethyl-4-phenylbutanoyl chloride 

Relevant articles and documents

THERAPEUTIC AGENT FOR DIABETES

A therapeutic agent for diabetes, which comprises a compound of the formula [I] wherein Xis a group of the formula wherein R4and R5are the same or different and each is a hydrogen atom, an optionally substituted alkyl having 1 to 5 carbon atoms and the like, and R6is a hydrogen atom or an amino-protecting group; R1is an optionally substituted alkyl having 1 to 5 carbon atoms, an optionally substituted alkenyl having 2 to 6 carbon atoms and the like, R2is a hydrogen atom, an optionally substituted alkyl having 1 to 5 carbon atoms and the like, R2' is a hydrogen atom, and R3is an optionally substituted alkyl having 1 to 5 carbon atoms and the like, a prodrug thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof and a solvate thereof. The compound of the present invention shows superior blood sugar decreasing action on the state of hyperglycemia, but does not affect the blood sugar when it is in the normal range or in the hypoglycemic state, which means that it is free of serious side effects such as hypoglycemia. Therefore, the compound of the present invention is useful as a therapeutic drug for diabetes and also useful as a preventive of the chronic complications of diabetes.

Conformational Analysis of 1- and 3-Isopropylindoles. A 1H NMR and Molecular Mechanics Study

The conformations of the isopropyl groups in a series of 1- and 3-isopropylindoles have been studied by 1H NMR and molecular mechanics technique.The isopropyl group is shown to assume both syn and an anti conformation, and the equilibrium between these is shown to depend on the steric size of the substituent in position 2.The syn form is relatively more favoured in the 3- than in the 1-isopropylindoles, which can be explained by differences in the lengths of the ring bonds to N-1 and C-3.The energy barriers to syn-anti exchange are 45-46 kJ mol-1 in the 1-iPr compounds when R2=Me or CO2Me.This barrier is lower in the 3-iPr analogues and could only be measured when R1=iPr, R2=Me (35 kJ mol-1).In the 1-iPr compounds a 3-Me group exerts no observable buttressing effect on a 2-Me group, unlike the situation in 1-iso-propylnaphthalenes, where introduction of a 3-Me group leads to an apparent diminution of the steric effect of the 2-Me group ("negative buttressing").In 1-isopropyl-2-methylindole a 3-Br also exerts a negative buttressing effect.